Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
BioTime, Inc. (NY: BTX)
4.380 USD  +0.200 (+4.78%)
Official Closing Price  /  Updated: 6:40 PM EDT, May 24, 2013  /  Add to My Watchlist      
View: Quote News Research
All news about BioTime, Inc.
 
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Biotonix Closes First Tranche of Private Placement
March 21, 2012
from Marketwired
BioTime CEO Michael D. West to Present at 2012 Maxim Group Growth Conference
March 21, 2012
from Business Wire News Releases
CORRECTING AND REPLACING BioTime Announces Fourth Quarter and Fiscal Year End 2011 Financial Results and Recent Corporate Accomplishments
March 14, 2012
from Business Wire News Releases
BioTime, Inc. (BTX) Reports Q4 Loss of $0.10
March 14, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7269728 for the full story. Read More
from StreetInsider.com News Articles
BioTime to Present at ROTH 24th Annual Growth Stock Conference
March 08, 2012
from Business Wire News Releases
Biotonix annonce une entente finale visant la prise de contrôle inversée par The Atman Co.
February 27, 2012
from Marketwired
Biotonix Announces Final Agreement for Reverse Takeover by The Atman Co.
February 27, 2012
from Marketwired
BioTime CEO Michael D. West to Present at New York Stem Cell Summit
February 17, 2012
from Business Wire News Releases
Biotonix annonce un placement privé sans l'entremise d'un courtier
February 16, 2012
from Marketwired
Biotonix Announces Private Placement Without Broker
February 16, 2012
from Marketwired
BioTime Licenses Technology for Key Regulatory Gene Underlying Cancer and Stem Cell Reprogramming from The Wistar Institute
January 24, 2012
from Business Wire News Releases
BioTime (BTX) to Market Progenitors of Muscle Stem Cells
January 03, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7048638 for the full story. Read More
from StreetInsider.com News Articles
BioTime (BTX) Announces Plans to Begin Producing Stem Cells for Research in Muscle Disorders
January 03, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7048637 for the full story. Read More
from StreetInsider.com News Articles
BioTime to Produce Stem Cells for Research in Muscle Disorders
January 03, 2012
from Business Wire News Releases
The Week in Review: Hutchison MediPharma and AstraZeneca Partner on Cancer Drug
December 24, 2011
Hutchison MediPharma and AstraZeneca formed a partnership to develop a novel cancer molecule; Hua Medicine in-licensed global rights to diabetes treatment program; Shunfeng Pharma is auctioning itself... Read More
from ChinaBio® Today
BioTime Options Cell Lines from USCN Life Science China
December 23, 2011
BioTime of the US has signed an agreement with USCN Life Science China, giving BioTime an option to license USCN's antibody-producing cell lines. BioTime and its OncoCyte subsidiary may use the cell... Read More
from ChinaBio® Today
Biotonix annonce une entente de principe visant une prise de contrôle inversée avec the Atman Co.
December 22, 2011
from Marketwired
Biotonix Announces an Agreement in Principle for a Reverse Takeover with the Atman Co.
December 22, 2011
from Marketwired
SHAW, MIND, BTX, AMGN Among Charts to Watch
December 22, 2011
The stock market had a topsy-turvy session on Wednesday, and although their was a lack of follow-through, it did close up on the day. We’re going to go over some interesting chart patterns here, and... Read More
from Charts of the Day by Harry Boxer
BioTime Signs Agreement with USCN Life Science to Source Antibody-Based Products
December 21, 2011
from Business Wire News Releases
WBB Securities Upgrades BioTime, Inc. (BTX) to Strong Buy
December 19, 2011
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7029403 for the full story. Read More
from StreetInsider.com News Articles
BioTime (BTX), Subsidiary Aim to Launch PanC-Dx in Europe by FY13
December 16, 2011
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7025776 for the full story. Read More
from StreetInsider.com News Articles
BioTime’s Subsidiary OncoCyte Corporation Announces Plans for the Novel Pan-Cancer Diagnostic Product PanC-DxTM
December 16, 2011
from Business Wire News Releases
BioTime Successfully Completes HyStem®-Rx Preclinical ISO 10993 Studies
December 12, 2011
from Business Wire News Releases
BioTime, Inc. Appoints Andrew C. von Eschenbach, M.D. to its Board of Directors
November 29, 2011
from Business Wire News Releases
Biotonix annonce les résultats du troisième trimestre de 2011
November 22, 2011
from Marketwired
Biotonix Announces Third Quarter 2011 Results
November 22, 2011
from Marketwired
WBB Securities Upgrades BioTime, Inc. (BTX) to Buy
November 16, 2011
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=6955877 for the full story. Read More
from StreetInsider.com News Articles
BioTime Cell Information Now Available in GeneCards®
November 14, 2011
from Business Wire News Releases
BioTime, Inc. (BTX) Reports Q3 Loss of $0.08
November 08, 2011
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=6927000 for the full story. Read More
from StreetInsider.com News Articles
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here